Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Klinik für Nuklearmedizin
Prof. Dr. Samer Ezziddin
Sie befinden sich hier: >> Startseite >> Klinische Zentren und Einrichtungen >> Klinische Zentren und Einrichtungen am UKS >> Radiologie >> Nuklearmedizin >> Patient Information In English >> Alpha-Therapy of bone metastases (Xofigo, Ra 223)

Alpha-Therapy of bone metastases (Xofigo, Ra 223)

Alpha-Therapy of bone metastases (Xofigo, Ra 223)

The targeted radionuclide therapy of bone metastases with the alpha particle emitter Radium-223 (Xofigo®) is offered by our department. A major international study has shown that treatment with Xofigo prolongs the survival in patients with bone metastases from prostate carcinoma, even in patients in whom antihormone therapy and chemotherapy are no longer effective. A lasting pain reduction was also observed.


Therapy procedure


Xofigo therapy consists of 6 intravenous injections in 4 week intervals. Treatment is administered on an outpatient basis, you need to stay in the clinic for 1 to 2 hours at a time. On the first appointment you should be able to spend more time, as we will inform you in detail about the therapy and if necessary, perform the necessary examinations (e.g. skeletal scintigraphy, blood tests and other imaging studies, if not already available). Xofigo injections are painless and usually without acute side effects. You may leave after therapy. In certain cases an inpatient treatment may be necessary.


Case Report Xofigo

82y old male prostate carcinoma patient with bone metastases recieved 6 treatment cycles of Radium-223 (Xofigo®). PSA levels declined after Ra-223 treatment and quality of life was significanlty improved with a progression-free survial of 19 months. Therapy monitoring was performed by 68Ga-PSMA-11 PET imaging.

Is treatment with Xofigo an option for you?


Xofigo is indicated in patients with bone metastases and is also covered by the statutory health insurance in the presence of prostate cancer, if pain due to bone metastases and a failure of hormone therapy have been documented. We urge you to talk to your urologist or oncologist about this therapy option. They can tell you if this is an option for you. You may as well contact us directly and introduce yourself for a consultation. In any case, we will give you detailed advice and if necessary, recommend additional examinations prior to therapy. The form required for registration is available on request. We will request documents from you or your doctor or arrange an appointment with you by telephone.


What do I have to consider during therapy?


No special preparation is required. You should bring the documents you have about your illness with you or ask your doctor to send them to us. A fasting state is not required on the day of treatment.

Case management

Mrs. Kerstin Sutter

Tel.: +49 (0) 6841 1624594
Fax: +49 (0) 6841 161724594